**Appendix - Table 1. Neonatal prophylaxis type by birth period in 6503 study children**

|  |  |  |
| --- | --- | --- |
|  |  | **Birth period** |
|  |  | **1996-2003** | **2004-2010** | **2011-2016** | **TOTAL** |
|  |  | **Infected/****total** **n (%)** | **Infected/****total****n (%)** | **Infected/****total** **n (%)** | **Infected/****Total****n (%)** |
| **Types of Combination prophylaxis** | **ZDV+sdNVP**  | 4/53 (7.4) | 2/20 (10.0) | 0/17 (0.0) | 6/90(7.9) |
| **ZDV+sdNVP+3TC** | 0/3 (0.0) | 3/38 (7.9) | 0/16 (0.0) | 3/57 (5.3) |
| **ZDV+NVP (2 doses) +3TC** | 0/0 (0.0) | 0/0 (0.0) | 0/2 (0.0) | 0/2 (0.0) |
| **ZDV+NVP (3 doses)** | 0/1 (0.0) | 0/0 (0.0) | 0/2 (0.0) | 0/3 (0.0) |
| **ZDV+3TC** | 2/14 (14.3) | 1/19 (5.3) | 1/10 (10.0) | 4/43 (9.3) |
| **ZDV+3TC+LPV+RTV** | 0/0 (0.0) | 0/8 (0.0) | 2/7 (28.6) | 1/15 (13.3) |
| **ZDV+3TC+NFV** | 0/0 (0.0) | 0/1 (0.0) | 0/0 (0.0) | 0/1 (0.0) |
| **ZDV+DDI** | 0/0 (0.0) | 0/1 (0.0) | 0/0 (0.0) | 0/1 (0.0) |
| **ZDV+LPV+RTV** | 0/0 (0.0) | 0/0 (0.0) | 0/2 (0.0) | 0/2 (0.0) |

**Note.**  ZDV, zidovudine; NVP, nevirapine; 3TC, lamivudine; LPV, lopinavir; RTV, ritonavir; NFV, nelfinavir; DDI, didanosine; sd, single dose.

**Appendix – Table 2**

**Univariate and multivariate analysis for risk factors for HIV-1 infection in 6098 children followed up since birth**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Univariate analysis** | **Multivariate analysis** |
|  | **Infected/total (%)** | **OR** **(95% CI)** | **P** | **OR** **(95% CI)** | **P** |
|  |  |  |  |  |  |
| **Sex** |   |   |   |   |   |
| Male | 56/3149 (1.78%) | 1 |   | 1 |   |
| Female | 85/2949 (2.88%) | 1.64 (1.16-2.31) | 0.005 | 1.75 (1.22-2.52) | 0.002 |
|  |  |  |  |  |  |
| **Birth period** |   |   |   |   |   |
| 1996-2003 | 96/2783 (3.45%) | 1 |   | 1 |   |
| 2004-2010 | 36/2480 (1.45%) | 0.41 (0.28-0.61) | <0.0001 | 1.04 (0.66-1.65) | 0.859 |
| 2011-2016 | 9/835 (1.08%) | 0.30 (0.15-0.61) | 0.001 | 1.17 (0.53-2.58) | 0.696 |
|  |  |  |  |  |  |
| **Mother nationality** |   |   |   |   |   |
| Italian  | 26/1453 (1.79%) | 1 |   |   |   |
| Foreign  | 41/2185 (1.88%) | 1.05 (0.64-1.72) | 0.848 |   |   |
| Missing | 74/2460 (3.01%) | 1.70 (1.08-2.67) | 0.021 |   |   |
|  |  |  |  |  |  |
| **Delivery idem** |   |   |   |   |   |
| Elective Caesarean | 67/4941 (1.36%) | 1 |   | 1 |   |
| Non-Elective Caesarean | 16/533 (3.00%) | 2.25 (1.30-3.91) | 0.004 | 2.11 (1.18-3.78) | 0.012 |
| Vaginal with detectable viral load | 57/438 (13.01%) | 10.88 (7.53-15.73) | <0.0001 | 3.29 (2.15-5.04) | <0.0001 |
| Vaginal with undetectable viral load | 0/117 (0.00%) |  |  |  |  |
| Missing | 1/70 (1.43%) | 1.05 (0.14-7.70) | 0.958 | 0.31 (0.04-2.39) | 0.264 |
|  |  |  |  |  |  |
| **Gestational age** |   |   |   |   |   |
| >37 weeks | 81/3485 (2.32%) | 1 |   |   |   |
| 33-37 weeks | 40/2266 (1.77%) | 0.76 (0.51-1.11) | 0.150 |   |   |
| <32 weeks | 10/236 (4.24%) | 1.86 (0.95-3.64) | 0.070 |   |   |
| Missing | 10/111 (9.01%) | 4.16 (2.09-8.26) | <0.0001 |   |   |
|  |  |  |  |  |  |
| **ART duration** |  idem |   |   |   |   |
| >4 weeks | 40/4529 (0.88%) | 1 |   | 1 |   |
| <4 weeks | 19/381 (4.99%) | 5.89 (3.38-10.27) | <0.0001 | 3.25 (1.83-5.78) | <0.0001 |
| None | 78/679 (11.49%) | 14.56 (9.85-21.52) | <0.0001 | 4.98 (3.12-7.95) | <0.0001 |
| Missing | 4/509 (0.79%) | 0.89 (0.32-2.49) | 0.823 | 0.60 (0.21-1.71) | 0.344 |
|  |  |  |  |  |  |
| **Intrapartum i.v. zidovudine** |   |   |   |   |   |
| Yes | 56/4738 (1.18%) | 1 |   | 1 |   |
| No | 84/1296 (6.48%) | 5.79 (4.11-8.17) | <0.0001 | 1.04 (0.63-1.71) | 0.873 |
| Missing | 1/64 (1.56%) | 1.33 (0.18-9.74) | 0.781 | 0.73 (0.09-5.81) | 0.768 |
|  |  |  |  |  |  |
| **Maternal viral load at delivery** |  idem |   |   |   |   |
| <400 copies/mL | 3/2755 (0.11%) | 1 |   |   |   |
| >400 copies/mL | 30/724 (4.14%) | 39.65 (12.07-130.31) | <0.0001 | 20.88 (6.17-70.69) | <0.0001 |
| Missing | 108/2619 (4.12%) | 39.45 (12.51-124.41) | <0.0001 | 16.04 (4.87-52.83) | <0.0001 |
|  |  |  |  |  |  |
| **Neonatal prophylaxis** |   |   |   |   |   |
| 1 drug | 78/5219 (1.49%) | 1 |   | 1 |   |
| 2-3 or more drugs | 14/199 (7.04%) | 4.99 (2.77-8.97) | <0.0001 | 1.63 (0.83-3.18) | 0.153 |
| None | 49/657 (7.46%) | 5.31 (3.68-7.68) | <0.0001 | 1.54 (0.95-2.50) | 0.079 |
| Missing | 0/23 (0.00%) |  |   |   |   |